Antihypertensives to Avoid in AKI on ESRD
In patients with acute kidney injury superimposed on end-stage renal disease, ACE inhibitors and ARBs should be temporarily discontinued within 48 hours of AKI onset, and NSAIDs must be strictly avoided. 1, 2
Primary Agents to Discontinue
Renin-Angiotensin System Inhibitors (ACE-I/ARBs)
Temporary discontinuation of RAS inhibitors during AKI episodes improves mortality outcomes. The most recent high-quality evidence demonstrates that stopping ACE inhibitors or ARBs within 2 days of AKI detection reduces 30-day all-cause mortality (4.36% vs 5.91%, risk difference -1.55%) 1. This benefit persists at 180 days and applies even to patients with ESRD who develop superimposed AKI.
The mechanism is straightforward: during AKI, angiotensin II becomes necessary to maintain glomerular filtration pressure through efferent arteriolar constriction. Blocking this compensatory mechanism with ACE-I/ARBs can precipitate oliguric or anuric renal failure 3. While these agents are not contraindicated in stable ESRD patients on dialysis, the acute hemodynamic stress of AKI changes the risk-benefit calculation.
Key clinical pitfall: Under-recognition of AKI is the most common reason (73% of cases) for inappropriate continuation of RAS inhibitors 2. Continuation during AKI increases non-recovery rates from 29.6% to 58.6% 2.
NSAIDs - Absolute Avoidance
NSAIDs must be completely avoided in this population. They inhibit prostaglandin synthesis, which is critical for maintaining renal perfusion during hemodynamic stress 4, 5. The combination of NSAIDs with ACE-I/ARBs creates a "triple whammy" effect (especially when combined with diuretics) that dramatically increases AKI risk 5.
Secondary Agents Requiring Caution
Potassium-Sparing Diuretics
Spironolactone and eplerenone should be avoided in patients with significant renal dysfunction 6. In the context of AKI on ESRD, these agents pose severe hyperkalemia risk. The 2017 ACC/AHA guidelines explicitly state to avoid these agents with K+ supplements, other K-sparing diuretics, or significant renal dysfunction 6.
Thiazide and Thiazide-Like Diuretics
The ACC/AHA guidelines recommend avoiding thiazides in patients with GFR <45 mL/min 6. In ESRD with superimposed AKI, these agents are ineffective and should not be used.
Direct Renin Inhibitors (Aliskiren)
Aliskiren carries increased risk of hyperkalemia in CKD and can cause acute renal failure 6. It should be avoided in this population, particularly given the lack of proven benefit over ACE-I/ARBs in ESRD.
Agents That Can Be Continued
Calcium Channel Blockers
CCBs are nondialyzable and serve as appropriate second-line therapy for BP control in ESRD patients 7. They can be safely continued during AKI episodes as they do not depend on renal prostaglandin synthesis or affect glomerular hemodynamics adversely.
Beta-Blockers
Beta-blockers can generally be continued, though attention must be paid to dialyzability. Atenolol and nadolol are dialyzable, while metoprolol and carvedilol are not 8. For patients with cardiovascular disease or heart failure, continuing beta-blockers during AKI is often appropriate 7.
Alpha-2 Agonists and Direct Vasodilators
Clonidine and hydralazine can be used, though they are generally reserved as last-line agents due to side effects 6. They do not directly worsen renal hemodynamics during AKI.
Practical Management Algorithm
- Within 48 hours of AKI detection: Discontinue all ACE-I/ARBs and NSAIDs
- Verify discontinuation of: Potassium-sparing diuretics, thiazides, aliskiren
- Maintain for BP control: CCBs, beta-blockers, clonidine, hydralazine as needed
- After AKI resolution: Restart RAS inhibitors once kidney function stabilizes and volume status normalizes 3, 9
Critical caveat: The proven mortality benefit of ACE-I/ARBs in heart failure and post-MI patients means they should be restarted promptly after AKI resolution 3. The temporary discontinuation during acute injury does not negate their long-term benefit in ESRD patients with cardiovascular indications.